Preclinical Research
Our extensive experience in the academic sector, in a Big Pharma framework, and current global synergies and contract research services with large Biotech companies enable our TH Observatory Programme Medicine Discovery R&D to progressively build a high-capacity Preclinical Assay Platform and assessment services.
Also, FTH's stakeholders and collaborators advanced facilities guarantee fast turnaround times due to the high automation of the screening platform. FTH Preclinical Integrated solution follows pharmaceutical industry standards to be applied to high performance preclinical analysis involving in vitro and in vivo screening studies, in vivo efficacy studies, mechanism of action, description studies and safety studies.
Preclinical research services include:
Drug Metabolism:
-
Human CYP450 Inhibition
-
Human CYP450 Induction
-
Hepatotoxicity
-
Metabolite Profiling and Identification by high-resolution mass spectrometry
Neurotoxicity:
-
Serotonin Receptor Assays
-
Dopamine Receptor Assays
Genotoxicity:
-
MTT Assay
-
Cytotoxicity
Cardiotoxicity. Ion Channel Inhibition:
-
hERG
-
Nav1.5
-
Cav1.2
Mitochondrial Assays:
-
ROS
-
Superoxides
-
Mitochondrial Calcium
-
ATP/AMP/ADP Levels
-
NADH Concentration
-
Oxygen Consumption
The FTH RP Programme:
A combination of repositioned medicines to combat neurodegeneration
At the Teófilo Hernando Foundation (FTH) we are currently developing a Repositioning Programme (RP) seeking neuroprotective properties in medicines already approved. The RP Programme searches for medicines having neuroprotective properties by acting on one of the complex pathogenic pathways which are common to various neurodegenerative diseases. The hypothesis behind the Programme analyses the invasion -with a triad of medicines- of three of the pathogenic pathways leading to neuronal death, looking for additive or synergic neuroprotection, in order to delay disease progression.